Heterologous DNA-prime/protein-boost immunization with a monomeric SARS-CoV-2 spike antigen redundantizes the trimeric receptor-binding domain structure to induce neutralizing antibodies in old mice
暂无分享,去创建一个
R. Schirmbeck | R. Gross | K. Stifter | L. Krutzke | J. Kroschel | Alina Seidel | Dominik Pflumm | Fabrice Klein | Stefan Kochanek | Jan Münch | Reinhold Schirmbeck | Lea Krutzke
[1] Dae-Sun Kim,et al. Analyzing immune responses to varied mRNA and protein vaccine sequences , 2023, NPJ vaccines.
[2] J. Nguyen-Van-Tam,et al. Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A Randomised Controlled Trial , 2023, Journal of Infection.
[3] Hangwen Li,et al. Long-Term Cross Immune Response in Mice following Heterologous Prime-Boost COVID-19 Vaccination with Full-Length Spike mRNA and Recombinant S1 Protein , 2023, Vaccines.
[4] S. Fukushi,et al. Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain , 2023, Nature Communications.
[5] Li Yang,et al. Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5‐included SARS‐CoV‐2 variants than homologous vaccination of mRNA vaccine , 2023, MedComm.
[6] Kun Xu,et al. A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults , 2023, Frontiers in Immunology.
[7] S. Chatterjee,et al. Association of COVID-19 with Comorbidities: An Update , 2023, ACS pharmacology & translational science.
[8] M. Colombo,et al. Receptor‐binding domain‐based SARS‐CoV‐2 vaccine adjuvanted with cyclic di‐adenosine monophosphate enhances humoral and cellular immunity in mice , 2023, Journal of medical virology.
[9] William T. Harvey,et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness , 2023, Nature Reviews Microbiology.
[10] Michael E. DeWitt,et al. Frailty impacts immune responses to Moderna COVID-19 mRNA vaccine in older adults , 2023, Immunity & Ageing.
[11] A. Jin,et al. Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice , 2022, iScience.
[12] Yuhang Jiang,et al. A Vaccine of SARS-CoV-2 S Protein RBD Induces Protective Immunity , 2022, International journal of molecular sciences.
[13] G. Rimmelzwaan,et al. Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults , 2022, Nature Aging.
[14] Siti Norussaadah Mohd Salleh,et al. Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose , 2022, Nature Communications.
[15] Bin Zhou,et al. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial , 2022, The Lancet Infectious Diseases.
[16] I. Shimomura,et al. GRP78, a Novel Host Factor for SARS-CoV-2: The Emerging Roles in COVID-19 Related to Metabolic Risk Factors , 2022, Biomedicines.
[17] F. Kirchhoff,et al. BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults , 2022, Frontiers in Immunology.
[18] S. Hägg,et al. COVID vaccination in older adults , 2022, Nature Microbiology.
[19] Wenjun Liu,et al. The Cross-Protective Immunity Landscape Among Different SARS-CoV-2 Variant RBDs , 2022, Frontiers in Immunology.
[20] Chia-Yeh Liu,et al. Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy , 2022, Journal of biomedical science.
[21] Jim Q. Ho,et al. COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes , 2022, Frontiers in Immunology.
[22] M. Worobey,et al. Competent immune responses to SARS-CoV-2 variants in older adults following two doses of mRNA vaccination , 2022, Nature Communications.
[23] Li-Li Liu,et al. A Third Dose of an Inactivated Vaccine Dramatically Increased the Levels and Decay Times of Anti-SARS-CoV-2 Antibodies, but Disappointingly Declined Again: A Prospective, Longitudinal, Cohort Study at 18 Serial Time Points Over 368 Days , 2022, Frontiers in Immunology.
[24] M. Llorian,et al. Impaired immune response drives age-dependent severity of COVID-19 , 2022, bioRxiv.
[25] K. Giri,et al. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India , 2022, The Lancet.
[26] B. B. Stocks,et al. Characterization of a SARS-CoV-2 spike protein reference material , 2022, Analytical and Bioanalytical Chemistry.
[27] F. Kashanchi,et al. Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy , 2022, Medical Microbiology and Immunology.
[28] D. Montefiori,et al. Homologous and Heterologous Covid-19 Booster Vaccinations , 2022, The New England journal of medicine.
[29] F. Kirchhoff,et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants , 2021, EBioMedicine.
[30] H. Jäck,et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic , 2021, Cell.
[31] D. C. Swarts,et al. Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants , 2021, mBio.
[32] D. Tsiantoulas,et al. The Dynamics of B Cell Aging in Health and Disease , 2021, Frontiers in Immunology.
[33] Bärbel Camara,et al. Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults , 2021, Nature Microbiology.
[34] E. Verdin,et al. SARS-CoV-2, COVID-19 and the aging immune system , 2021, Nature Aging.
[35] F. Cosset,et al. Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination , 2021, Nature.
[36] V. Libri,et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial , 2021, The Lancet.
[37] J. Klingström,et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination , 2021, The New England journal of medicine.
[38] J. Münch,et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination , 2021, Nature Medicine.
[39] L. Vaca,et al. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants , 2021, Frontiers in Immunology.
[40] X. Xia. Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines , 2021, Vaccines.
[41] Chaim A. Schramm,et al. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants , 2021, Science.
[42] Frances E. Muldoon,et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 , 2021, Nature.
[43] J. Chou,et al. A Trimeric Hydrophobic Zipper Mediates the Intramembrane Assembly of SARS-CoV-2 Spike , 2021, Journal of the American Chemical Society.
[44] M. Cho,et al. A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain , 2021, Frontiers in Immunology.
[45] D. Gong,et al. Enhancing the Prefusion Conformational Stability of SARS-CoV-2 Spike Protein Through Structure-Guided Design , 2021, Frontiers in Immunology.
[46] C. Shin,et al. Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice , 2021, Vaccines.
[47] K. Subbarao,et al. Vaccines for older adults , 2021, BMJ.
[48] Charles Y. Tan,et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2 , 2021, Nature.
[49] N. Patel,et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice , 2021, Nature Communications.
[50] R. Varadarajan,et al. Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative , 2021, bioRxiv.
[51] Arlo Z. Randall,et al. Diverse Humoral Immune Responses in Younger and Older Adult COVID-19 Patients , 2021, medRxiv.
[52] K. Machida,et al. The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection , 2021, Journal of Biological Chemistry.
[53] Shixia Wang,et al. DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses , 2021, Emerging microbes & infections.
[54] Xiaojie Shi,et al. Neutralizing antibodies targeting SARS-CoV-2 spike protein , 2020, Stem Cell Research.
[55] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[56] B. Blomberg,et al. Aging induces B cell defects and decreased antibody responses to influenza infection and vaccination , 2020, Immunity & ageing : I & A.
[57] Yunwei Lou,et al. The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens , 2020, Frontiers in Immunology.
[58] R. Baric,et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults , 2020, The New England journal of medicine.
[59] M. Beltramello,et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.
[60] J. Schrag,et al. Rapid, high-yield production of full-length SARS-CoV-2 spike ectodomain by transient gene expression in CHO cells , 2020, bioRxiv.
[61] J. Diallo,et al. Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization , 2020, Membranes.
[62] Yuquan Wei,et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity , 2020, Nature.
[63] Ilya J. Finkelstein,et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes , 2020, Science.
[64] L. Renault,et al. Stabilizing the closed SARS-CoV-2 spike trimer , 2020, Nature Communications.
[65] A. Sette,et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients , 2020, Science Immunology.
[66] M. Fain,et al. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes , 2020, GeroScience.
[67] B. Graham,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.
[68] Shiliang Ma,et al. B Cell Dysfunction Associated With Aging and Autoimmune Diseases , 2019, Front. Immunol..
[69] R. Schirmbeck,et al. Cationic domains in particle-forming and assembly-deficient HBV core antigens capture mammalian RNA that stimulates Th1-biased antibody responses by DNA vaccination , 2018, Scientific Reports.
[70] N. Petrovsky,et al. DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant. , 2017, The Journal of general virology.
[71] Fang Li,et al. Structure, Function, and Evolution of Coronavirus Spike Proteins. , 2016, Annual review of virology.
[72] A. Mondal,et al. The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination , 2014, Human vaccines & immunotherapeutics.
[73] R. Viscidi,et al. Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates. , 2013, Viral immunology.
[74] B. Blomberg,et al. In senescence, age‐associated B cells secrete TNFα and inhibit survival of B‐cell precursors * , 2013, Aging cell.
[75] M. Cancro,et al. A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. , 2011, Blood.
[76] J. Arthos,et al. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. , 2010, Vaccine.
[77] Hongxiang Sun,et al. ISCOMs and ISCOMATRIX. , 2009, Vaccine.
[78] Shan Lu. Heterologous prime-boost vaccination. , 2009, Current opinion in immunology.
[79] C. Siegrist,et al. B-cell responses to vaccination at the extremes of age , 2009, Nature Reviews Immunology.
[80] R. Vaughan,et al. B-cell diversity decreases in old age and is correlated with poor health status , 2009, Aging cell.
[81] S. Kochanek,et al. Recombinant complexes of antigen with stress proteins are potent CD8 T-cell-stimulating immunogens , 2008, Journal of Molecular Medicine.
[82] D. Weiskopf,et al. Biology of immune responses to vaccines in elderly persons. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[83] Giuseppe Altavilla,et al. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. , 2006, Vaccine.
[84] Kim L Kusser,et al. Age-related Defects in CD4 T Cell Cognate Helper Function Lead to Reductions in Humoral Responses , 2004, The Journal of experimental medicine.
[85] R. Rappuoli,et al. Synthesis and Characterization of a Native, Oligomeric Form of Recombinant Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein , 2004, Journal of Virology.
[86] T. Randall,et al. CD4 T cell memory derived from young naive cells functions well into old age, but memory generated from aged naive cells functions poorly , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[87] J. Reimann,et al. Priming polyvalent immunity by DNA vaccines expressing chimeric antigens with a stress protein‐capturing, viral J‐domain , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[88] J. Reimann,et al. Truncated or chimeric endogenous protein antigens gain immunogenicity for B cells by stress protein‐facilitated expression , 1999, European journal of immunology.
[89] S. Green,et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. , 2008, Vaccine.